Malignant Mesothelioma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ATM
ATM Loss
ATM Mutation
ATR
ATR Loss
ATR Mutation
BAP1
BAP1 Deficient Expression
BAP1 Loss
BAP1 Mutation
BARD1
BARD1 Loss
BARD1 Mutation
BRCA1
BRCA1 Loss
BRCA1 Mutation
BRCA2
BRCA2 Loss
BRCA2 Mutation
BRIP1

BRIP1 Loss
BRIP1 Mutation
CDK12
CDK12 Loss
CDK12 Mutation
CDKN2A No Expression
CHEK1
CHEK1 Loss
CHEK1 Mutation
CHEK2

CHEK2 Loss
CHEK2 Mutation
FANCA
FANCA Loss
FANCA Mutation
FANCB
FANCB Loss
FANCB Mutation
FANCC
FANCC Loss

FANCC Mutation
FANCD2
FANCD2 Loss
FANCD2 Mutation
FANCE
FANCE Loss
FANCE Mutation
FANCF
FANCF Loss
FANCF Mutation

FANCG
FANCG Loss
FANCG Mutation
FANCI
FANCI Loss
FANCI Mutation
FANCL
FANCL Loss
FANCL Mutation
FANCM

FANCM Loss
FANCM Mutation
MCPH1
MCPH1 Loss
MCPH1 Mutation
MRE11A
MRE11A Loss
MRE11A Mutation
NBN
NBN Loss

NBN Mutation
NF2
NF2 Deficient Expression
NF2 Loss
NF2 Mutation
PALB2
PALB2 Loss
PALB2 Mutation
PD-L1 Expression
PD-L1 High Expression

PD-L1 Low Expression
PTEN
PTEN Loss
PTEN Mutation
RAD50
RAD50 Loss
RAD50 Mutation
RAD51
RAD51 Loss
RAD51 Mutation

RAD51B
RAD51B Loss
RAD51B Mutation
RAD51C
RAD51C Loss
RAD51C Mutation
RAD51D
RAD51D Loss
RAD51D Mutation
RAD54L

RAD54L Loss
RAD54L Mutation
SLX4
SLX4 Loss
SLX4 Mutation
TNFRSF8 Expression

Overview

NCI Definition: A malignant neoplasm of the pleura or peritoneum, arising from mesothelial cells. It is associated with exposure to asbestos. [1]

Malignant mesotheliomas most frequently harbor alterations in BAP1, NF2, CDKN2A, CDKN2B, and TP53 [2].

Most Commonly Altered Genes in Malignant Mesothelioma

CDKN2A Loss, CDKN2B Loss, BAP1 Mutation, BAP1fs, and NF2 Mutation are the most common alterations in malignant mesothelioma [2].

Top Alterations in Malignant Mesothelioma

Clinical Trials

View Clinical Trials for Malignant Mesothelioma

There are 8 clinical trials for malignant mesothelioma, of which 6 are open and 2 are completed or closed. Of the trials that contain malignant mesothelioma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (4 open).

BAP1, ATM, and ATR are the most frequent gene inclusion criteria for malignant mesothelioma clinical trials [3].

Trials Investigating Malignant Mesothelioma by Gene and Recruiting Status

Olaparib, pemetrexed, and abemaciclib are the most common interventions in malignant mesothelioma clinical trials.

Drugs Being Investigated in Malignant Mesothelioma Trials by Recruiting Status

Significant Genes in Malignant Mesothelioma

ATM +

ATM is altered in 4.59% of malignant mesothelioma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR +

ATR is altered in 1.29% of malignant mesothelioma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

BAP1 +

BAP1 is altered in 46.24% of malignant mesothelioma patients [2].

BAP1 is an inclusion eligibility criterion in 2 clinical trials for malignant mesothelioma, of which 1 is open and 1 is closed. Of the trials that contain BAP1 status and malignant mesothelioma as inclusion criteria, 2 are phase 2 (1 open) [3].

BARD1 +

BARD1 is altered in 1.34% of malignant mesothelioma patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 +

BRCA1 is altered in 1.94% of malignant mesothelioma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 +

BRCA2 is altered in 3.88% of malignant mesothelioma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRIP1 +

BRIP1 is altered in 0.28% of malignant mesothelioma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 +

CDK12 is altered in 0.32% of malignant mesothelioma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK1 +

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 +

CHEK2 is altered in 1.11% of malignant mesothelioma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA +

FANCA is altered in 1.95% of malignant mesothelioma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCB +

FANCB is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC +

FANCC is altered in 0.28% of malignant mesothelioma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCD2 +

FANCD2 is altered in 1.54% of malignant mesothelioma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE +

FANCE is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCF +

FANCF is altered in 1.04% of malignant mesothelioma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCG +

FANCG is altered in 0.52% of malignant mesothelioma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCI +

FANCI is altered in 1.92% of malignant mesothelioma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCL +

FANCL is altered in 3.51% of malignant mesothelioma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCM +

FANCM is altered in 3.85% of malignant mesothelioma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

MCPH1 +

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A +

MRE11A is altered in 0.89% of malignant mesothelioma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN +

NBN is altered in 0.84% of malignant mesothelioma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

NF2 +

NF2 is altered in 28.41% of malignant mesothelioma patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and malignant mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PALB2 +

PALB2 is altered in 1.39% of malignant mesothelioma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN +

PTEN is altered in 3.74% of malignant mesothelioma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD50 +

RAD50 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51 +

RAD51 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51B +

RAD51B is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C +

RAD51C is altered in 1.81% of malignant mesothelioma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51D +

RAD51D is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD54L +

RAD54L is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 +

SLX4 is altered in 1.92% of malignant mesothelioma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

Malignant Tumor of Mesothelium, Malignant Tumor of the Mesothelium, Malignant Neoplasm of the Mesothelium, Malignant Neoplasm of Mesothelium, MESOTHELIOMA, MALIGNANT, Malignant Mesothelial Neoplasm, Malignant Neoplasm c/w Malignant Mesothelioma, Malignant Mesothelial Tumor

Parent(s)

Mesothelioma

Children

Malignant Pleural Mesothelioma, Pericardial Malignant Mesothelioma, Ovarian Malignant Mesothelioma, Peritoneal Malignant Mesothelioma, and Diffuse Malignant Mesothelioma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Malignant Mesothelioma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Malignant Mesothelioma

Disease Details

References

About

Molecular Medicine

Content Types